Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


WeightSmart ads

This article was originally published in The Tan Sheet

Executive Summary

Bayer TV spot for newest One-A-Day line extension targets women ages 30 and older. "I remember when I thought I could eat anything," a female character says. "Then in my thirties my metabolism slowed down, so I got smart. I watch what I eat, exercise more, plus I found a new multivitamin." The ad, which broke Jan. 2, notes WeightSmart contains EGCG, "a natural green tea extract to help you while you manage your weight." Other ingredients highlighted on packaging include chromium, niacin, thiamin; product also contains caffeine powder. Marketing support for WeightSmart, which began reaching shelves this month, includes Jan. 5 FSI. BBDO is agency of record (1"The Tan Sheet" Oct. 28, 2002, In Brief)...

You may also be interested in...

One-A-Day for weight control

Bayer expects to reach 4 mil. consumers by placing ads, coupons for its new One-A-Day WeightSmart line extension in Weight Watchers direct mailings starting in December. TV spots by ad agency BBDO (Chicago) will break in January as the product reaches store shelves, Bayer says; Weight Smart will begin shipping Nov. 15. Labeling claims for the supplement include "ephedra free," "convert food to fuel with extra chromium and key B vitamins" and "specially formulated to help you while you control your weight." WeightSmart also contains green tea extract "to enhance your metabolism." Suggested retail price is $7.49 for a 50-count bottle, $12.99 for 100 tablets...

UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts